Dyspnea and Cardiotoxicity in Multiple Myeloma Patients Who Receive Carfilzomib
NCT ID: NCT04827563
Last Updated: 2025-01-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
50 participants
OBSERVATIONAL
2021-03-22
2026-08-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Subcutaneous Daratumumab, Once Weekly Carfilzomib, and Dexamethasone (DKd) in Patients With High-Risk Smoldering Multiple Myeloma
NCT04933539
Carfilzomib, Cyclophosphamide, Dexamethasone in Transplant Eligible Newly Diagnosed High-risk Multiple Myeloma
NCT02217163
High Dose Carfilzomib for Newly Diagnosed Myeloma
NCT02937571
Carfilzomib, Lenalidomide, and Dexamethasone Before and After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma
NCT01816971
A Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly-Diagnosed Multiple Myeloma
NCT04268498
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Participants with Normal Baseline Endothelial Function
EndoPAT
An FDA approved device to test the health of a patient's blood vessels, which involves putting an oxygen probe on the participant's finger.
Blood Pressure Cuff
A device used to conduct blood pressure monitoring using a home blood pressure cuff that participant wears for 24 hours.
Echocardiogram
A test used to conduct an ultrasound of participant's heart.
Quality of Life Assessment
A survey that will be given to participants to report their quality of life and symptoms related to multiple myeloma.
Blood Tests
Routinely collected for all participants who begin carfilzomib treatment.
Participants with Abnormal Baseline Endothelial Function
EndoPAT
An FDA approved device to test the health of a patient's blood vessels, which involves putting an oxygen probe on the participant's finger.
Blood Pressure Cuff
A device used to conduct blood pressure monitoring using a home blood pressure cuff that participant wears for 24 hours.
Echocardiogram
A test used to conduct an ultrasound of participant's heart.
Quality of Life Assessment
A survey that will be given to participants to report their quality of life and symptoms related to multiple myeloma.
Blood Tests
Routinely collected for all participants who begin carfilzomib treatment.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
EndoPAT
An FDA approved device to test the health of a patient's blood vessels, which involves putting an oxygen probe on the participant's finger.
Blood Pressure Cuff
A device used to conduct blood pressure monitoring using a home blood pressure cuff that participant wears for 24 hours.
Echocardiogram
A test used to conduct an ultrasound of participant's heart.
Quality of Life Assessment
A survey that will be given to participants to report their quality of life and symptoms related to multiple myeloma.
Blood Tests
Routinely collected for all participants who begin carfilzomib treatment.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Confirmed diagnosis of multiple myeloma
* Newly-diagnosed multiple myeloma, or relapsed/refractory multiple myeloma with receipt of 1-3 previous lines of therapy and with a 2-week washout from prior therapy
* Receiving carfilzomib as either standard-of-care therapy or as part of a clinical trial
Exclusion Criteria
* Previous receipt of carfilzomib
* Four or more previous lines of therapy
* Active pregnancy at the time of enrollment
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Chicago
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jeanne DeCara, MD
Role: PRINCIPAL_INVESTIGATOR
University of Chicago - Comprehensive Cancer Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Chicago
Chicago, Illinois, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IRB20-1768
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.